2023-09-04 09:53:43 ET
More on Cyclacel Pharmaceuticals
- Cyclacel Pharmaceuticals Inc. ( CYCC ) Q2 2023 Earnings Call Transcript
- Cyclacel Pharmaceuticals GAAP EPS of -$0.60 misses by $0.12
- Cyclacel stock rises 16% as net loss narrows, income grows
- Cyclacel Pharmaceuticals jumps on preclinical data for blood cancer treatment fadraciclib
- Cyclacel Pharmaceuticals reveals plans for cancer drug programs for 2022
- Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals
- Earnings data for Cyclacel Pharmaceuticals
For further details see:
Cyclacel Pharmaceuticals files for $100M mixed shelf offering - filing